Really don't have a clue what the amount is.Some have said on this board its 7,8,9,10,12.Which 7 would be great to me.Seems like we getting the cart in front of the horse.
All I know is this we first got to get positive results regarding this ongoing trial which may come anyday then we can throw it around.I do think going to phase II would trigger a milestone payment.
I just look at whats been filed with the SEC and this pr from Intellect which makes it pretty clear its a serious dollar amount if all works out regarding Shire.
Thats not the only thing going for Intellect I'm telling you that CONJUMAB platform to me is worth more then everything including Tau,Pfizer PONEZUMAB or GSK imho and to me its not being worked like it should be again just my opinion its golden.
If you not going to push it ahead sell it is all I say!
In September 2011, we entered into an Exclusive License Agreement with ViroPharma Inc. related to OX1. In January 2014, ViroPharma merged with Shire Plc. Shire is developing OX1 as a treatment for Friedreich's Ataxia and possibly other diseases for which OX1 may qualify for orphan drug designation. Under the terms of the License Agreement, we agreed to transfer to ViroPharma all of our intellectual property rights, data and know-how related to our OX1 research and development program in exchange for payment by ViroPharma of a $6.5 million up-front licensing fee and additional regulatory milestone payments based upon defined events in the United States and the European Union. The aggregate maximum of these milestone payments assuming successful advancement of the product to market could amount to $120 million. In addition, ViroPharma will pay us a tiered royalty based on annual net sales.
News 
Market Data 
Discover 
